ArticleBMC medicine2024
Prevalence and differences in the co-administration of drugs known to interact: an analysis of three distinct and large populations.
Article in BMC medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Interest in complementary and alternative medicine among participants in a study on cancer prevention by green tea extract - results from an expert-based survey of MIRACLE trial participants.BMC complementary medicine and therapies · 2025Trial
- Development and analysis of a SmPC-based machine-readable dataset of contraindications for clinical decision support and real-world data analysis.European journal of clinical pharmacology · 2026Article
- Article
- Prevalence, predictors, and clinical relevance of drug-drug interactions in outpatient prescribing: A national cross-sectional study.PloS one · 2026Article
- myAURA: a personalized health library for epilepsy management via knowledge graph sparsification and visualization.Journal of the American Medical Informatics Association : JAMIA · 2026Article
- Benzodiazepine (BZD) Use and Patient Safety: Opportunities for Community Pharmacy Involvement in the Management of Drug Interactions.Pharmacy (Basel, Switzerland) · 2025Article
- Focused digital cohort selection from social media using the metric backbone of biomedical knowledge graphs.Journal of biomedical informatics · 2025Article
- The health care needs of multidimensional frail elderly patients with multimorbidity in primary health-care settings: a qualitative study.BMC primary care · 2025Article
- Probing the in-depth analysis of Serious Adverse Drug Reactions in a tertiary care hospital of Central India.Exploratory research in clinical and social pharmacy · 2025Article
- Challenges and opportunities for digital twins in precision medicine from a complex systems perspective.NPJ digital medicine · 2025Review
- The association of prescriber prominence in a shared-patient physician network with their patients receipt of and transitions between risky drug combinations.Applied network science · 2025Article
- Potential Adverse Drug Events Identified with Decision Support Algorithms from Janusmed Risk Profile-A Retrospective Population-Based Study in a Swedish Region.Pharmacy (Basel, Switzerland) · 2024Article
Corrections and comments
- Update of
Authors and funding
7 authors at 6 institutions in 5 countries.
Funding
Abstract
backgroundThe co-administration of drugs known to interact greatly impacts morbidity, mortality, and health economics. This study aims to examine the drug-drug interaction (DDI) phenomenon with a large-scale longitudinal analysis of age and gender differences found in drug administration data from three distinct healthcare systems.
methodsThis study analyzes drug administrations from population-wide electronic health records in Blumenau (Brazil; 133 K individuals), Catalonia (Spain; 5.5 M individuals), and Indianapolis (USA; 264 K individuals). The stratified prevalences of DDI for multiple severity levels per patient gender and age at the time of administration are computed, and null models are used to estimate the expected impact of polypharmacy on DDI prevalence. Finally, to study actionable strategies to reduce DDI prevalence, alternative polypharmacy regimens using drugs with fewer known interactions are simulated.
resultsA large prevalence of co-administration of drugs known to interact is found in all populations, affecting 12.51%, 12.12%, and 10.06% of individuals in Blumenau, Indianapolis, and Catalonia, respectively. Despite very different healthcare systems and drug availability, the increasing prevalence of DDI as patients age is very similar across all three populations and is not explained solely by higher co-administration rates in the elderly. In general, the prevalence of DDI is significantly higher in women - with the exception of men over 50 years old in Indianapolis. Finally, we show that using proton pump inhibitor alternatives to omeprazole (the drug involved in more co-administrations in Catalonia and Blumenau), the proportion of patients that are administered known DDI can be reduced by up to 21% in both Blumenau and Catalonia and 2% in Indianapolis.
conclusionsDDI administration has a high incidence in society, regardless of geographic, population, and healthcare management differences. Although DDI prevalence increases with age, our analysis points to a complex phenomenon that is much more prevalent than expected, suggesting comorbidities as key drivers of the increase. Furthermore, the gender differences observed in most age groups across populations are concerning in regard to gender equity in healthcare. Finally, our study exemplifies how electronic health records' analysis can lead to actionable interventions that significantly reduce the administration of known DDI and its associated human and economic costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.